Potential Role of Navitoclax in Myelofibrosis and T-Cell Acute Lymphoblastic Leukemia

home / news-network / potential-role-of-navitoclax-in-myelofibrosis-and-t-cell-acute-lymphoblastic-leukemia

Expert perspectives on the emerging role of navitoclax, a novel BCL-XL inhibitor, in the treatment armamentarium for myelofibrosis and T-cell acute lymphoblastic leukemia, respectively.

EP. 1: Overview on Myelofibrosis: Diagnosis, Staging, and Molecular Testing

By Naveen Pemmaraju, MD

February 2nd 2023

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

EP. 2: Disease Modification in Myelofibrosis: The Current Treatment Paradigm

By Naveen Pemmaraju, MD

February 2nd 2023

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

EP. 3: Interpreting Data From the REFINE Study: Ruxolitinib + Navitoclax in Myelofibrosis

By Naveen Pemmaraju, MD

February 2nd 2023

Expert perspectives on specific subsets of the REFINE study, which combined ruxolitinib with navitoclax in patients diagnosed with myelofibrosis.

EP. 4: Unmet Needs and Future Directions in the Management of Myelofibrosis

By Naveen Pemmaraju, MD

February 2nd 2023

Naveen Pemmaraju, MD, highlights unmet needs in the setting of myelofibrosis management and looks toward future evolutions in the treatment paradigm.